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Abstract
Historically, the progress of long term-oxygen therapy (LTOT) in Japan has been characterized by collaboration among academic 
groups, policy makers, and industrial companies. The public health insurance program has covered the cost of LTOT since 1985. 
Thomas Petty’s group in Denver enthusiastically carried out the public implementation of LTOT and conveyed the concept of pul-
monary rehabilitation for the processing with LTOT. Although the target diseases of LTOT in Japan tended to be chronic obstructive 
pulmonary disease or sequelae of primary lung tuberculosis, it was soon applied for cardiac diseases as well as other pulmonary 
diseases. Together with increasing medical costs for geriatric patients, the political conversion from hospital based care of 
a traditional style to home care system has been performed, with two background reasons: the improvement of quality of life of 
patients and the reduction of the medical expense. Presently, LTOT plays a pivotal role in the successful implementation of home 
respiratory care for elderly patients. In addition, this promotes comprehensive pulmonary rehabilitation, a team approach, and 
close liaisons between primary care and hospitals. Currently, the total number of patients using LTOT exceeds 150,000. In Japan, 
LTOT resulted in an advancement in the medical care as well as in administrative decision to introduce it as a nationwide system 
after analyzing the results of opinion polls of patients with respiratory failure. However, the recent great earthquake in East Japan 
revealed that many unresolved problems remain for these patients, and these issues are of great concern.
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Introduction 
It is no exaggeration to say that the recent 
respiratory care system in Japan has been devel-
oped in parallel with the progress of long-term 
oxygen therapy (LTOT), which is widely referred 
to as home oxygen therapy in this country. Home 
treatment has expanded rapidly in Japan since 
the 1980s. This can be attributed to the increase 
in the elderly population, the resulting rise in 
the number of chronically ill patients, and the 
sharp increase in medical expenditure for the 
nation. By mid-century, the chance of surpassing 
thresholds of individuals aged over 60 was 98% in 
Japan/Oceania, 82% in Western Europe, and 69% 
in China [1]. The focus of medical treatment has 
been shifting away from hospital-based medical 
care, especially the acute care that became the 
norm after World War II, and has moved toward 
quality of life. This achievement has had many 
spill-over effects, including the development of 
medical equipment that can be used at home for 
treating the elderly, encouragement for the de-
velopment of the medical care system by a team 
of multi-disciplinary specialists and health care 
professionals, intensification of the debate over 
the quality of respiratory care, and the advance-
ment of comprehensive pulmonary rehabilitation. 
In addition, developments in the related area of 
LTOT continuously raise the awareness of pa-
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piratory Failure Research Group from the Ministry 
of Health, Labour, and Welfare, Japan. According 
to Kawakami, one of the oxygen pioneers in Japan 
[7], the historical course toward LTOT in Japan is 
divided into three phases. The first phase com-
prises accomplishments in basic research (from 
1978 to 1986), in which defining the respiratory 
failure, its criteria, and both pathophysiology 
and treatments subsequently clarified the va-
lidity of LTOT. The second phase (from 1987 to 
1995) comprises the period during which many 
questions were raised. Specifically, this phase 
involved questions regarding monitoring methods 
for pathophysiological aspects, proposing LTOT 
guidelines, related examinations and treatments, 
and the construction of a concept for a home-care 
system.The third phase (from 1996 to the pres-
ent) comprises the settlement of these scientific 
achievements, which includes the development 
of a home-care system including comprehensive 
pulmonary rehabilitation, monitoring methods 
for home care, strategies for severe dyspnoea 
and pulmonary hypertension, technological 
developments for ambulatory oxygen, revision 
of LTOT criteria, and the benefits from the view 
of medical expenditures. In parallel with these 
movements, industrial entities have made efforts 
to develop concentrators and ambulatory oxygen 
systems with demand valves, which make saving 
oxygen during walk or exercise possible. The Fire 
Prevention Law, which previously did not allow 
the use of oxygen at home or on public transpor-
tation, has been changed accordingly, providing 
an example of cooperation by policy makers. 
Thus, all barriers or surrounding problems for 
LTOT were properly addressed in order to move 
toward subsequent coverage by public health 
care insurance for LTOT. Concomitant with these 
movements by policy makers and companies, the 
Japan Respiratory Society (JRS) determined cri-
teria for LTOT in 1984, and LTOT was thereafter 
covered by public health insurance in 1985. The 
initial criteria were based on data from two mile-
stone clinical trials in the USA [8] and the UK [9]. 
These studies demonstrated that LTOT used in 
COPD patients prolonged survival, reduced sec-
ondary polycythaemia, and improved pulmonary 
haemodynamics and neuropsychological func-
tion. In 2004, chronic congestive heart failure 
with Cheyne-Stokes breathing during sleep was 
added as a new criterion, which emphasizes the 
role of nocturnal and intermittent hypoxaemia 
in the pathophysiology of chronic respiratory 
failure. However, two above mentioned studies 
tients against traditional and unsociable medicine 
for chronic respiratory diseases, particularly for 
patients with pulmonary tuberculosis. This re-
view will discuss aspects of LTOT that are unique 
to its historical development, present status, and 
perspective in Japan. 
Historical aspects of long-term  
oxygen therapy in Japan
In 1798, Thomas Beddose established the 
Pneumatic Institute in Bristol, England, by apply-
ing the oxygen originally discovered by Priestly. 
He began to use oxygen to treat heart disease, 
asthma, and opium poisoning. The scientific stud-
ies of John Scott Haldane and Joseph Barcroft on 
oxygen deficiency in humans defined the benefits 
of oxygen therapy, Alvan Barach in New York, and 
Albert Andrews, Edwin Levine, and Max Sadove 
in Chicago are credited with providing education 
to those who were assigned to learn about oxygen 
therapy. Alvan Barach and Thomas Petty in Den-
ver were friends during the time that Petty and his 
colleagues began their study on LTOT with liquid 
portable oxygen in the mid-1960s [2]. Later, Petty 
described a memento he received from Barach in 
1958, in which a cartoon depicting oxygen-sup-
ported exercise by using a small portable cylinder 
had been enclosed [3]. This suggestion, which 
promoted suitable exercise under oxygen use, 
subsequently came to fruition with the develop-
ment of LTOT-based pulmonary rehabilitation for 
patients by the Denver group. These promising 
achievements, subsequently have materialized 
later for LTOT in connection with two major 
findings in Japan. First, during the late 1970s 
and early 1980s, Clark and Severinghaus elec-
trodes were adapted for transcutaneous clinical 
application. Further, Takuo Aoyagi accidentally 
discovered pulse oximetry in Tokyo while he 
was attempting to measure dye indicator cardiac 
output with an ear probe [2]. Sapporo, Kawakami 
et al. [4] performed cardiac catheterization on 
patients with stable chronic obstructive pulmo-
nary disease (COPD) with or without pulmonary 
hypertension, and the outcomes were compared 
after 4 years. Their observations with oxygen 
inhalation have provided physiological evidence 
for improved diffusion limitation and prolonged 
life expectancy. 
The history of LTOT in Japan has been influ-
enced by academic groups in collaboration with 
policy makers and industrial companies [5, 6]. 
The academic groups were mostly led by the Res-
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Figure 1. Annual changes in the number of patients receiving long-term oxygen therapy in Japan
Table 1.  Eligibility standards for public health insurance 
coverage of LTOT in Japan
1. Cyanotic congenital heart disease
2. Cases of advanced chronic respiratory failure
Patients with arterial oxygen tension of 55 mm Hg or less 
while using LTOT or patientswith arterial oxygen tension of 
60mmHg who experience severe hypoxaemia whensleeping or 
exercising whose doctors determine that LTOT is necessary
3. Pulmonary hypertension
4. Chronic heart failure
Based on a doctor’s diagnosis, patients that are classified as 
NYHA III or higher, exhibit Cheyne-Stokes respiration when sle-
eping, and an apnoea/hypopnoea index (an index of the number 
of complete cessations and partial obstructions of breathing 
occurring per hour of sleep) of 20 or higher confirmed by using 
polysomnography
Extracted from the Ministry of Health, Labour and Welfare, Japan (2008) [7]
[8, 9] are based on data in COPD patients less 
than 70 years of age, whereas most of the patients 
using LTOT in Japan are over 70 years of age, 
suggesting lack of data for these elderly patients. 
A distinguishing feature of the Japanese criteria 
that they cover patients with COPD in addition 
to patients with other lung diseases and cardiac 
diseases, the latter of which comprises cyanotic 
congenital heart disease or chronic congestive 
heart disease. In addition to adult patients, the 
number of paediatric patients with chronic res-
piratory failure caused by various lung diseases or 
cardiac diseases has reached approximately 4,000 
(personal communication from Professor Saji, 
Toho University School of Medicine, Tokyo). Thus, 
a characteristic of LTOT in Japan is that it includes 
all generations, from children to elderly patients, 
and all patients are equally covered under public 
health insurance; however, the criteria for children 
have not been established yet. 
 Despite the contributions of the academic 
groups, the pace at which LTOT was being in-
troduced to physicians throughout Japan was 
too slow. Thomas Petty (1932–2009), who played 
a pivotal role in the development of LTOT in the 
1960s, greatly contributed to introducing LTOT 
to Japan. His most important and far-reaching 
accomplishment was the introduction of LTOT for 
the treatment of chronic lung disease, particularly 
COPD. He also is one of the first to demonstrate 
the beneficial effects of pulmonary rehabilitation 
programs for patients recently discharged from 
the intensive care unit and for those with COPD. 
The combined concept of LTOT and pulmonary 
rehabilitation was conveyed by Petty and many 
of his colleagues; this began in 1985 in Japan and 
continues until this day [10]. 
From the late 1980s through the 1990s, 
the environment surrounding LTOT in Japan 
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dramatically improved. The implementation 
of LTOT changed from the pre-authorization 
system to the registration system by the au-
thorities, although the latter remained a bar-
rier to expansion to general physicians. The 
registration system was abolished after the 
prescription and management of LTOT were 
extended to clinics without inpatient services. 
Relaxing the regulations resulted in the expan-
sion of LTOT from chest physician specialists 
to general physicians. This solved the issue of 
disproportionate medical management with re-
gard to urban areas versus rural areas, the latter 
of which has a more limited number of chest 
physician specialists. Furthermore, an indica-
tion for pulmonary hypertension was added to 
the criteria. The current criteria for eligibility 
for LTOT in Japan are shown in Table 1. These 
changes contributed to the steady increase in 
the number of LTOT patients in Japan. Accord-
ing to data of the Medical Gas Association in 
Japan, it is assumed that approximately 150,000 
people used home oxygen therapy (HOT) as of 
2009; although estimating the precise number 
of patients with LTOT is difficult, a speculative 
number can be obtained from industrial sourc-
es. The annual changes in the number of LTOT 
patients and related topics are shown in Figure 
1, which reveals that the number of patients 
increased because of several interventions by 
policy makers. 
Comprehensive pulmonary rehabilitation  
combined with the use of LTOT 
In 1994, a research group supported by the 
Ministry of the Environment started a project 
to study the benefit of LTOT for pulmonary 
rehabilitation, as advocated by Petty and col-
leagues. This project, led by the author of this 
article, has continued for a total of 16 years and 
has contributed to the initial development of 
pulmonary rehabilitation in Japan. Until this 
period, pulmonary rehabilitation in Japan was 
mainly realized by physiotherapists. Further, 
the physiotherapists merely guided the patients, 
most of whom had sequelae of lung tuberculosis 
(TBsq), in postural drainage or breathing tech-
niques through diaphragm training, but this was 
not a comprehensive program for patients with 
COPD. Our working hypothesis, combined with 
both LTOT and comprehensive pulmonary re-
habilitation, was proposed in 1995 [11], after an 
inspection of modern pulmonary rehabilitation in 
the USA. Subsequently, this concept was adopted 
with respect to the clinical guidelines of both the 
Japan Society for Respiratory Care (2003) and 
the JRS (2003, 2009, and 2013). The hypothesis 
is mainly an instruction for patients with LTOT 
and comprises 7 different components, as shown 
in Figure 2. In this concept, the combined roles 
of nutrition and exercise as basic education for 
patients with LTOT and his/her family members 
Figure 2. Framework of comprehensive pulmonary rehabilitation for patients with LTOT
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is emphasized. Instruction regarding smoking 
cessation for these patients is another important 
option, because sporadic fire accidents due to 
smoking were reported in the early stage of LTOT. 
It is considered that LTOT in Japan has produced 
secondary progress or awareness in all areas of re-
spiratory care, which includes a wide spectrum of 
health care professionals. Because it is interesting 
to view these effects from an academic viewpoint 
by utilizing published data,a systematic review 
of the literature was conducted to identify data 
related to LTOT published from 1983 to March, 
2013.The PubMed database was searched by 
using the following defined search terms: “long-
term oxygen therapy” or “home oxygen therapy”. 
The total number of hits for manuscripts written 
in English language was 744 and, among them, 
47 were from Japan as of March 2013. However, 
when the same term was used for searching the 
literature for reports written in Japanese and pu-
blished in this country, the amount reached ap-
proximately 2,500. Most reports regarding LTOT 
are described as original research (n=1,528) or 
as an educational review (n=1,081) and were 
conducted by academic physicians and chest 
specialists or health care professionals. Thus, 
the progression of LTOT has resulted in a pa-
rallel increase in medical staff in the entire area 
related to chronic respiratory care or pulmonary 
rehabilitation. These movements also result in 
greater recognition that patients with disability 
due to chronic respiratory failure are increasing 
in number and emphasize their right to receive 
equal or better treatments. In 2006, a monograph 
of clinical guidelines for oxygen therapy was 
published in collaboration with the Japanese 
Respiratory Society and the Japanese Society for 
Respiratory Care & Rehabilitation. Furthermore, 
two textbooks on pulmonary rehabilitation for 
health care professionals were published in 2003 
and 2007, respectively, by the same societies. The 
first book, which was released in 2012, is a manu-
al for exercise therapy, and the second one is for 
patient education on various respiratory diseases, 
particularly for patients with COPD. Further, 
the total number of respiratory physiotherapists 
who received training and passed examinations 
reached approximately 30,000 in 2012. A new 
system for qualified nurses for respiratory care 
has started in 2011 with the support of the Japan 
Nursing Association, and these trainees will have 
a central role in respiratory care in the future, 
particularly for patients with COPD. These effects 
are all derived from the establishment of LTOT 
in Japan.
Survey of LTOT in Japan
In 2005, the JRS first published the Japanese 
White Paper on Home Respiratory Care [12], which 
is a summary of surveys from patients with chro-
nic respiratory failure, general physicians, and 
qualified chest physicians. This is the first report 
to consider the responses of both physicians and 
patients on LTOT. 
This report included a total of 4,341 medical 
institutes, which comprised institutions accre-
dited by the JRS (n = 534), randomly selected 
general hospitals (n = 2,307), and institutions 
related to the Japan Physicians Association (n = 
1,500). The breakdown of reported LTOT patients 
(Fig. 3A) is similar to that in the aforementioned 
report by the former Ministry of Health and 
Welfare [13]. The most common disease was 
COPD, which was reported for approximately 
half of the patients, followed by TBsq. Although 
LTOT can be provided through clinics that have 
no inpatient services, these clinics accounted 
for only a few percentage points, whereas the 
majority of the patients received treatment by 
chest physician specialists. Survey data on those 
patients, which belonged to the Japan Federation 
of Patient Organization for Respiratory Diseases, 
is also of interest. Of the 2,237 people who retur-
ned a response, 55% were receiving LTOT and/or 
home mechanical ventilation. The mean flow rate 
of oxygen was less than 1 l/min and between 1 l 
and 2 l in 45% and 34%, respectively. Although 
70% of the patients were prescribed oxygen for 
24 hours, the precise hours of use (adherence) were 
not determined. Moreover, 28% of the patients 
showed PaO2 > 60 mmHg, suggesting that they 
did not fulfil the eligibility criteria for LTOT; ho-
wever, an improvement in breathlessness (91%), 
better activity of daily living (73%), and impro-
ved exercise capacity (55%) were observed after 
initiation of LTOT. The doctors mainly had an 
interest in the improvement of arterial blood gas 
or pulse oxymetry, whereas the matter of concern 
for patients was the improvement of breathlessness; 
in fact, 16% of these patients had their own pulse 
oximeter and many other wished to have one, 
suggesting that patients felt better regarding bre-
athlessness and were also concerned about oxygen 
saturation values. The matter of greatest concern or 
dissatisfaction after beginning LTOT was related to 
electric blackouts or natural disasters (57%). Indeed, 
these occurred during the Great Earthquakes in East 
Japan on March 11, 2011. 
Approximately 20,000 people were killed and 
66% of these individuals were over 60 years of 
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Figure 3. The breakdown of patients who received LTOT (long-term oxygen therapy) in Japan
age. In the aftermath of this natural disaster, the 
problems occurring among elderly patients were 
poor access to medication, medical equipment, 
and medical supplies. A retrospective cohort 
study [14] was conducted at a regional medical 
centre, the Ishinomaki Red Cross Hospital, Mi-
Pneumonologia i Alergologia Polska 2013, tom 81, nr 5, strony 468–478 
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yagi, Japan, in the area affected most severely. 
The study was performed 6 months after the 
disaster. The characteristics, clinical courses, 
and outcomes of COPD patients hospitalized 
after emergency visits during the study period 
were investigated and compared. One hundred 
patients (112 episodes) were identified. Within 
a few days after the disaster, patients undergoing 
oxygen therapy at home came to the hospital to 
receive oxygen. In the sub-acute phase (from 
the third to the fifth week), the number of hos-
pitalizations due to COPD exacerbations was 
significantly higher than the numbers observed 
before the earthquake (p < 0.05). On admission, 
COPD patients reported significantly reduced 
participation in the activities of daily living after, 
as compared to before the disaster. The incidence 
of cases of exacerbated COPD normalized 6 weeks 
after the earthquake. Many patients with LTOT 
felt victims and became refugees. For instance, at 
least 100 people gathered to seek a power source 
for a concentrator and had to stay at least several 
days at the centre hospital (personal communica-
tion, Professor Yanai of the Ishinomaki Red Cross 
Hospital, Miyagi) because of electric blackouts at 
their homes. 
The survey data indicate that 94% of patients 
used a concentrator and portable oxygen, where-
as only 6% of the patients used liquid oxygen. 
More than 60% of the institutions replied that 
they provided comprehensive patient education 
at the time of LTOT initiation. Further, 83% 
of the patients had obtained physical disability 
certification in order to receive support for part 
of the expense of LTOT because each patient must 
pay out-of-pocket money ranging from approxi-
mately 5,000 to 12,000 yen (39–94 €) per month, 
even though the procedure is covered by public 
medical insurance. Only 45% of the patients 
received pulmonary rehabilitation. A summary 
of the data in the first survey of the Japanese 
White Paper on Home Respiratory Care indicates 
that LTOT in Japan is still prospering, but studies 
on the following aspects are required: (1) patient 
education and pulmonary rehabilitation, (2) the 
possibility of an early intervention, such as LTOT 
use for patients with PaO2 > 60 mm Hg, and (3) 
patients’ societies and the JRS should work in 
cooperation to improve social welfare and the 
social environment for patients with severe dis-
ability. Furthermore, improving the social envi-
ronment and proper maintenance and service for 
equipment used for LTOT are required, the latter 
of which is addressed to providers and includes 
a safety net for the equipment, tele-monitoring, and 
a strategy in the case of a great disaster. In order to 
arrange the new system, nurses specially trained 
in the care of patients with chronic respiratory 
disability are requested from the Japan Nursing 
association, the JRS, and the Ministry of Health 
and Welfare in Japan. All of these information in-
dicates a growing tendency towards improvement 
of the situation among patients with respiratory 
disability, who occasionally committed suicide at 
pre-LTOT era, because of too long hospitalization 
for oxygen treatment [5]. 
Accordingly, a second survey was performed 
in 2009 and the data were published in 2010 [15] 
in The Japanese White Paper on Home Respiratory 
Care. This study, which was performed on the 
same scale as the first one but used a different 
patient group, comprised a total of 5,043 medi-
cal institutes, including institutions accredited 
by the JRS (n = 804), randomly selected general 
hospitals (n = 2,739), and institutions related to 
the Japan Physicians Association (n = 1,500). 
A total of 824 responses were obtained from pa-
tients with LTOT and the mean age of the patients 
was 69.0 years. In the second survey, COPD was 
a leading disease (45%), followed by interstitial 
lung diseases (18%) and chronic congestive he-
art failure (CHF) with Cheyne-Stokes breathing 
(3%) (Fig. 3B). A comparison of the breakdown of 
the LTOT patients between the first and second 
surveys revealed that the percentages of COPD 
and TBsq had decreased [(48% Æ 45%) and (18% 
Æ 12%), respectively], whereas diffuse lung di-
seases and congestive heart failure with Cheyne
-Stokes breathing had increased [(15% Æ 18%) 
and (1% Æ 3%), respectively]. The prevalence 
of COPD in Japan (2001) is reportedly 8.6% of the 
general population over age 40, and approxima-
tely 1% of them receive LTOT [16]. Current data 
indicate that the number of patients with COPD 
is increasing in parallel to the increase in the 
geriatric population. Presumably, such patients 
are managed by primary care physicians or at 
general hospitals; however, a precise number 
of patients was not provided in the second survey. 
The overall data of the second survey was simi-
lar to the data of the first survey. Both revealed 
that LTOT strongly increased the awareness 
of patients and stimulated the activity of heath 
care professionals.
Research topics on LTOT 
Despite the importance of LTOT in the mana-
gement of COPD or other diseases in Japan, many 
deficits remain, according to our knowledge, re-
garding its mechanisms of action, indications for 
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prescription, and effects on patients’ outcomes. 
Both clinical decision-making and insurance co-
verage policies today are based mostly on research 
performed in the 1970s. Little has been done in 
the past 20 years and remarkably little research 
is currently being conducted in this area. 
Gender difference in outcomes
After medical insurance was applied to LTOT 
in 1985, the Respiratory Failure Research Group, 
supported by the Ministry of Health and Welfare, 
have continued the initiative in evaluating the 
usefulness and safety of LTOT. The Internation-
al Symposium on Domiciliary Respiratory Care 
was held in Tokyo (1993) and the proceedings 
of the Conference were published later [13, 17]. 
Separately, Miyamoto and associates [18] ana-
lysed sex-related differences in survival based on 
a very large population that had received LTOT 
from 1986 to 1993. A total of 9,759 patients with 
COPD, TBsq, and chronic interstitial pneumonia 
were selected in 1,212 medical institutions for 
analysis of survival rates. The mean survival peri-
ods of the women who died during the follow-up 
periods were significantly longer than those of 
the men, the difference was: 0.41 years for COPD, 
1.84 years for TBsq, and 0.78 years for chronic 
interstitial pneumonia. They concluded that 
women have a better prognosis compared to men 
when they begin receiving LTOT, regardless of the 
cause of respiratory failure. However, this study 
was the beginning of a dispute [19–21]. Machado 
and co-workers [22] reported that survival was 
significantly worse in females and in those with 
a lower body mass index and lower PaO2 in patients 
with COPD receiving LTOT. The reasons for these 
different conclusions are still not known. Survival 
is considered “fraught with complexities’’ and 
multiple comorbidities are likely to affect the 
complex clinical course in patients using LTOT. 
Ekströmand associates also reported [23] that 
survival was significantly better in women. They 
performed a prospective study of patients aged 
50 years or older who were starting long-term LTOT 
for COPD in Sweden between 1992 and 2008. In 
total, 8,712 patients (55% women) were included 
and 6,729 patients died during the study period. 
Compared with women, men had significantly 
more arrhythmia, cancer, ischemic heart disease, 
and renal failure, and less hypertension, mental 
disorders, osteoporosis, and rheumatoid arthritis 
(p < 0.05 for all odds ratios). Comorbidity was 
an independent predictor of mortality, and the 
effect was similar for the sexes. Women had lower 
mortality which remained unchanged even after 
adjusting for comorbidity: hazard ratio (HR), 
0.73 [95% confidence interval (CI), 0.68–0.77; 
p < 0.001]. Although the comorbidities were dif-
ferent in men and women, this does not explain 
the sex-related difference in mortality in oxy-
gen-dependent COPD. More recently, two inter-
esting studies have been published on this topic 
[24, 25]. A total of 213 patients with COPD (FEV1, 
51 ± 17% predicted; men, 59%; age, 64 ± 7 years) 
were included prospectively and studied by clus-
ter analysis [24]. Multimorbidity is common in 
patients with COPD, and different comorbidity 
clusters can be identified. Low-grade systemic 
inflammation is mostly comparable among co-
morbidity clusters. An increasing knowledge of 
the interactions between comorbidities enhances 
the understanding of their development and con-
tributes to strategies for prevention or improved 
treatment. It is estimated that the time-dependent 
effects of cardiovascular drugs on survival in ox-
ygen-dependent COPD account for the perpetual 
and immeasurable time bias [25]. Furthermore, 
a group from Sweden studied 2,249 COPD patients 
using LTOT [25], and 1,129 (50%) patients died 
during observation. The adjusted time-dependent 
model was compatible with reduced mortality for 
antiplatelet drugs (HR, 0.86; 95%CI, 0.75–0.99; 
p < 0.030) and a trend for reduced mortality for an-
giotensin-converting enzyme inhibitors or angioten-
sin receptor blockers (HR, 0.90; 95%CI, 0.79–1.04; 
p < 0.166) and statins (HR, 0.86; 95% CI, 0.72–1.03; 
p < 0.105), whereas b-blockers increased mortality 
(HR, 1.19; 95% CI, 1.04–1.37; p < 0.010) . They con-
cluded that anti-platelet drugs improve survival and 
b-blockers decrease survival in oxygen-dependent 
COPD. Thus, the controversy on the gender dif-
ference in the survival rate of COPD with LTOT is 
moving in the direction of the role of medications 
or multimorbidities. The gender difference in the 
outcomes of COPD provoked controversy, which 
has continued to a more recent period [25]. An 
initial study compared patients with LTOT due to 
various lung diseases in terms of gender difference 
[18], however, a more recent study revealed a gender 
difference in COPD patients alone. 
Hypercapnia in patients with LTOT
Another study from Japan [26] suggested 
that the hypercapnia observed in patients with 
chronic respiratory failure is not an ominous 
sign for prognosis when they are receiving LTOT. 
Aida and associates selected 4,552 patients with 
COPD and 3,028 with TBsq receiving LTOT from 
1985 to 1993 throughout Japan, and prospec-
tively analysed their prognoses. The hypercap-
Pneumonologia i Alergologia Polska 2013, tom 81, nr 5, strony 468–478 
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nic patients (PaCO2 > 45 mm Hg) had a better 
prognosis than did the normocapnic patients 
(35 < PaCO2, 45 mm Hg) for TBsq, but no dif-
ference was found between the 2 groups with 
COPD. Furthermore, Cox’s proportional hazards 
model revealed that in TBsq, hypercapnia was 
an independent factor for a favourable progno-
sis, and that the relative risk for mortality was 
0.76 in patients with 45 < PaCO2 < 55 mm Hg, 
0.64 for those with 55 < PaCO2 < 65 mm Hg, 
and 0.49 for patients with PaCO2 > 65 mm Hg, 
against normocapnic patients. This favourable effect 
of hypercapnia in TBsq was particularly apparent in 
the patients without severe airway obstruction. Even 
a rise of 5 mm Hg or more in PaCO2 over the initial 
6- to 18-month follow-up period was not associated 
with a poor prognosis in TBsq, although it was in 
COPD. From these findings, they concluded that 
hypercapnia should not generally be considered an 
ominous sign for prognosis in patients who receive 
LTOT [26]. The effects of hypercapnia on survival in 
COPD patients with LTOT are not discussed even in 
the recent research recommendation by the NIH [27]. 
However, because nasal positive-pressure ventilation 
may be a useful addition to LTOT in stable hyper-
capnic patients with COPD in terms of quality of life 
[28],this treatment option for patients with LTOT 
and hypercapnia should be also discussed in terms 
of better quality of life.
Moderate hypoxaemia  
or severe breathlessness
Among these proposals, the efficacy of LTOT 
in moderate hypoxaemia is important, although 
it was previously concluded that LTOT had no 
effect on prolonged survival among such patients 
[29]. However, the majority of patients with se-
vere COPD wish to be eligible for LTOT in order 
to improve severe breathlessness in daily life, as 
shown in the survey data [12]. 
Presently, this option is the greatest issue in 
research on LTOT. Breathlessness or dyspnoea is 
a term used to characterize a subjective experience 
of breathing discomfort that is comprised of quali-
tatively distinct sensations that vary in intensity. 
It encompasses multiple somatic perceptions that 
are variously described as air hunger, increased 
breathing effort, chest tightness, rapid breathing, 
incomplete exhalation, or a feeling of suffocation. 
Thus, it is known that dyspnoea is a major detriment 
to quality of life [30–32]. Dyspnoea is the perception 
that the respiratory muscle response is inadequate 
or unsustainable. This perception arises from the 
sensory cortex, which integrates information from 
multiple sources, including the peripheral and cen-
tral chemoreceptors, mechanoreceptors (arising from 
the large airways, lung parenchyma, and the chest 
wall), and respiratory motor centres (in the medulla 
as well as the motor cortex). A multidisciplinary 
approach to dyspnoea that addresses various patho-
physiological factors from symptom production to 
perception is required. Regarding the clinical aspects, 
nurses (education), physiotherapists (exercise thera-
py), respiratory therapists, occupational therapists 
(ergonomics and accommodation strategies), dieti-
cians (to optimize nutrition), and psychologists/ 
/chaplains (to address symptom meaning) all have 
important roles to play [33, 34]. 
Studies of supplemental oxygen for relief of 
dyspnoea have shown mixed results in hypoxa-
emic patients with cancer and severe lung disease; 
however, no study has suggested a benefit for non-
hypoxaemic patients [35]. Studies of supplemental 
oxygen for dyspnoea in advanced cancer,which 
included many cases in the Japanese cohort, are 
more complex. Based upon evidence of moderate 
quality, evidence-based guidelines from the Ameri-
can College of Physicians (ACP) recommend oxygen 
for the short-term relief of hypoxaemia in adults 
with dyspnoea and serious illness at the end of life 
[36, 37]. However, the presence of hypoxaemia does 
not reliably predict the symptomatic response from 
oxygen therapy [38, 39]. Studies of supplemental 
oxygen for relief of dyspnoea for palliative care 
have shown mixed results in hypoxaemic patients 
with cancer and severe lung disease. Alternative 
therapies such as acupuncture have been exami-
ned as potential therapies to reduce dyspnoea, and 
a retrospective series and a small randomized trial 
have shown mixes results [40, 41]. More recently, 
Suzuki et al. demonstrated [42] that acupuncture 
is a useful adjunctive therapy in reducing breath-
lessness in patients with COPD. 
These observations all suggest that the cur-
rent situation in Japan is more complex because 
more than half of the patients receiving LTOT 
do not have COPD, which means that they are 
receiving LTOT for conditions for which LTOT 
use is not supported by scientific data, and ap-
proximately 30% of these cases are presenting 
with moderate hypoxaemia. Further studies regar-
ding survival, quality of life, or other measurable 
outcomes are required in these patients.
Issues arising regarding LTOT for elderly 
patients 
Although the majority of patients with LTOT 
are elderly, knowledge regarding the effects of 
or issues associated with LTOT in these patients 
remains scarce. Elderly COPD patients may have 
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specific geriatric issues, such as the presence 
of multiple comorbidities, including cognitive 
impairment, medication adherence, caregiver 
involvement, and the necessity for institutiona-
lized care. COPD is particularly relevant in this 
context because the presence of lung disease is 
associated with a greater number of geriatric syn-
dromes (e.g. low body mass index, dizziness, and 
falls) and the risk of associated impairments in the 
activities of daily living. Recent work has further 
demonstrated an association between COPD seve-
rity and the risk of cognitive decline, specifically 
in chronically hypoxic or oxygen-dependent indi-
viduals with COPD [43, 44]. Moreover, COPD and 
cognitive impairment have each been associated 
with high rates of hospitalization [45] and death 
[46] in older adults. We reported data on elderly 
COPD patients using LTOT [47] with the objective 
of identifying factors that determine outcome in 
elderly patients receiving LTOT for COPD. We 
followed 157 COPD patients (121 men and 36 wo-
men) from 1983 to 1994, and 96 of these patients 
(61.2%) died. The mean age of the patients was 
79.2 years and the mean duration of LTOT was 
2.81 years. The mean FEV1 was 0.80 L and the 
mean FEV1/FVC was 48%. The overall survival 
was poor, with a 5-year survival of 21.6% (median 
survival: 3.01 years). Among the variables tested 
by univariate analysis, the following factors were 
associated with outcome: %IBW < 85 (HR = 2.15, 
p < 0.001), serum albumin (g/dl) < 3.5 (HR 1.81, 
p < 0.01), haemoglobin (g/dl) <11.0 (HR 1.86, 
p < 0.01), FEV1/FVC > 50% (HR 0.63, p < 0.05), 
and high dyspnoea ranking (MMRC 4 or 5) 
(HR 1.74, p < 0.05). The coexistence of bronchiectasis 
(HR 3.96, p < 0.01) and malignancy (HR 1.85, 
p < 0.01) also contributed to poor outcome. Multi-
variate analysis showed that the independent pro-
gnostic factors influencing outcome were nutritio-
nal status (%IBW) (HR = 2.08, p < 0.01), dyspnoea 
ranking (HR 2.04, P <0.01), the coexistence of 
malignancy (HR 2.02, p < 0.01), and FEV1/FVC 
> 50% (HR 0.52, p < 0.01). We conclude that the 
outcome in elderly COPD patients receiving LTOT 
is poor, and that outcome is independently influ-
enced by 4 major factors: malnutrition, severity 
of dyspnoea, the coexistence of malignancy, and 
airflow obstruction. 
A clinical trial is required in the future 
The National Heart, Lung, and Blood Insti-
tute, in collaboration with the Centres for Medi-
care and Medicaid Services, convened a working 
group to discuss research on LTOT in 2004 [27]. 
Although LTOT has been proven by clinical trials 
to prolong life in patients with COPD and severe 
resting hypoxaemia[9, 10], scientific research has 
not provided definitive guidance regarding who 
should receive LTOT and how it should be deli-
vered. Deficiencies in knowledge and in current 
research activity related to LTOT are especially 
striking in comparison to the importance of LTOT 
in the management of COPD and the associated 
costs. The NHLBI Workshop Report recommended 
following clinical trials in subjects with COPD 
[27]: (1) the efficacy of ambulatory O2 supple-
mentation in subjects who experience oxyha-
emoglobin desaturation during physical activity 
but are not severely hypoxaemic at rest; (2) the 
efficacy of LTOT in subjects with severe COPD 
and only moderate hypoxaemia; (3) the efficacy 
of nocturnal O2 supplementation in subjects who 
show episodic desaturation during sleep that is 
not attributable to obstructive sleep apnoea; and 
(4) the effectiveness of an activity-dependent 
prescription for the O2 flow rate that is based on 
clinical tests performed at rest, during exercise, 
and during sleep. In addition, the efficacy and 
cost-effectiveness for elderly patients should be 
assessed at two aspects: improvement of quality 
of life and cost-effectiveness. Furthermore, el-
derly patients are prone to having problems with 
understanding the instructions provided by the 
medical staff, which may cause low adherence. 
Previously, Zielinski noted an association [48] 
between low compliance and a lack of sufficient 
information regarding oxygen therapy provided to 
patients from prescribing physicians, indicating 
that proper education of patients is important. 
However, the data from our survey also indicate 
that education of the patients receiving LTOT 
remains insufficient because only one-third of 
patients received proper information, and this 
information came mostly from the technicians 
who delivered the oxygen equipment. 
Conclusions 
A quarter of a century has passed in Japan 
since public health insurance began covering 
LTOT in 1985. Comprehensive pulmonary reha-
bilitation has progressed along with an increased 
number of patients who receive LTOT. The awa-
reness of respiratory disability is rapidly growing 
among both patients and health care professio-
nals, which supports the further progress of LTOT 
in our country. However, further scientific studies 
are required to optimize LTOT in the patients 
with end-stage chronic lung diseases, because 
sufficient scientific evidence is lacking.
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